Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The ERBB (HER) family of receptor tyrosine kinases is often activated in cancer.
• Gene fusions involving the ERBB ligand NRG1 represent a newly identified mechanism for ERBB pathway dysregulation.

Purpose of the Study:

• To investigate the role of NRG1 gene fusions in cancer, specifically in lung adenocarcinomas.
• To explore the potential therapeutic implications of targeting ERBB2/ERBB3 in cancers with NRG1 fusions.

Main Methods:

• Identification and characterization of NRG1 gene fusions.
• Analysis of ERBB pathway activation (PI3K-AKT, MAPK) downstream of fusions.
• Correlation of fusion presence with specific lung adenocarcinoma subtypes (invasive mucinous, never-smokers).

Main Results:

• NRG1 gene fusions lead to cell-surface presentation of the EGF-like domain, activating ERBB3 and promoting ERBB2-ERBB3 heterodimerization.
• These fusions activate downstream PI3K-AKT and MAPK signaling pathways.
• NRG1 fusions were exclusively found in invasive mucinous lung adenocarcinomas from never-smokers, a disease subtype that is often multifocal and unresectable.

Conclusions:

• NRG1 fusions provide a novel mechanism for ERBB pathway activation in a specific subset of lung cancer.
• The presence of NRG1 fusions in invasive mucinous lung adenocarcinoma presents a potential therapeutic target.
• Targeting ERBB2 (HER2) and ERBB3 (HER3) with existing or developing drugs could be a viable treatment strategy for this aggressive disease.